Cooke J P, Dzau V J
Division of Cardiovascular Medicine, Stanford University, California 94305, USA.
Annu Rev Med. 1997;48:489-509. doi: 10.1146/annurev.med.48.1.489.
The product of nitric oxide (NO) synthase is the most potent endogenous vasodilator known. No not only is a potent vasodilator, it also inhibits platelet adherence and aggregation, reduces adherence of leukocytes to the endothelium, and suppresses proliferation of vascular smooth muscle cells. A number of disorders are associated with reduced synthesis and/or increased degradation of vascular NO. These include hypercholesterolemia, diabetes mellitus, hypertension, and tobacco use. The endothelial dysfunction caused by these disorders contributes to the alterations in vascular function and structure observed in these conditions. A reduction in the activity of vascular NO likely plays a significant role in the development of atherosclerosis. Insights into the mechanisms by which NO production or activity is altered in these states will lead to new therapeutic strategies in the treatment of a number of vascular disorders, including hypertension, atherosclerosis, restenosis, and thrombosis.
一氧化氮(NO)合酶的产物是已知最强效的内源性血管舒张剂。NO不仅是一种强效血管舒张剂,还能抑制血小板黏附和聚集,减少白细胞与内皮的黏附,并抑制血管平滑肌细胞增殖。许多疾病与血管NO合成减少和/或降解增加有关。这些疾病包括高胆固醇血症、糖尿病、高血压和吸烟。这些疾病引起的内皮功能障碍导致了在这些情况下观察到的血管功能和结构改变。血管NO活性降低可能在动脉粥样硬化的发展中起重要作用。深入了解这些状态下NO产生或活性改变的机制将为治疗包括高血压、动脉粥样硬化、再狭窄和血栓形成在内的多种血管疾病带来新的治疗策略。